Last reviewed · How we verify
Casein Phosphopeptide-Amorphous Calcium Phosphate
At a glance
| Generic name | Casein Phosphopeptide-Amorphous Calcium Phosphate |
|---|---|
| Also known as | (CPP-ACP), Tooth Mousse® (MI Paste®) (GC Corporation, Tokyo, Japan), (CPP-ACP) (MI paste) |
| Sponsor | Riyadh Elm University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of MI Paste Plus™ on Streptococcus Mutans and White Spot Lesions in Fixed Orthodontics (NA)
- Diode Laser Plus CPP-ACPF vs CPP-ACPF Alone for Dentin Hypersensitivity (NA)
- Effect Of Silverdiamine Fluoride Gel, Sodium Fluoride With CPP-ACP, APF On Early Childhood Caries - A Randomised Controlled Trial (PHASE2)
- Comparative Effectiveness of Remineralization Agents on Attachment-Associated Demineralization in Clear Aligner Patients (NA)
- Evaluation of Self-assembling Peptides Versus Amorphous Calcium Phosphate in the Treatment of White Spot Lesions (NA)
- Comparison of MI Paste Plus and Resin Infiltration in White Spot Lesions Following Orthodontic Treatment (NA)
- Exposed Hypersensitive Dentin Treated With Fluoride Iontophoresis With Remineralizing Agents (NA)
- Effect of Different Remineralizing Agents on White Spot Lesions Treatment in Children (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: